Finally, our findings also suggest that combination of PDGFR inhibition and sclerostin neutralization could represent a powerful approach to rapidly increase bone mass and strength in patients with osteolytic lesions provoked by multiple myeloma or bone metastases involving excessive PDGFR activity (24, 25). This evidence concerns the gene SOST and AL amyloidosis.